Citi Reaffirms Their Buy Rating on ProKidney (PROK)
Citi analyst Yigal Nochomovitz maintained a Buy rating on ProKidney today and set a price target of $10.00. The company’s shares closed yesterday at $2.24.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Nochomovitz is a 4-star analyst with an average return of 5.4% and a 39.59% success rate. Nochomovitz covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics, ProKidney, and Summit Therapeutics.
Currently, the analyst consensus on ProKidney is a Moderate Buy with an average price target of $5.80.
PROK market cap is currently $655.7M and has a P/E ratio of -3.72.
Read More on PROK:
Disclaimer & DisclosureReport an Issue
- ProKidney: Hold Rating Amid Encouraging Developments and Cautious Outlook
- ProKidney Corp. Reports Q2 2025 Financial Results
- ProKidney reports Q2 EPS (13c), consensus (14c)
- Prokidney Corp options imply 15.7% move in share price post-earnings
- Prokidney Corp options imply 13.0% move in share price post-earnings
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.